Check for updates

Role and interaction of bacterial sphingolipids in human health

Xiaoye Bai[1,2], Ru Ya[3], Xiaoyu Tang[2] and Mingwei Cai[2]*

[1]School of Medicine, Sun Yat-sen University, Shenzhen, China, [2]Shenzhen Bay Laboratory, Institute of Chemical Biology, Shenzhen, China, [3]Inner Mongolia Academy of Science and Technology, Hohhot, China

Sphingolipids, present in both higher animals and prokaryotes, involving in cell differentiation, pathogenesis and apoptosis in human physiological health. With increasing attention on the gut microbiome and its impact on wellbeing, there is a renewed focus on exploring bacterial sphingolipids. This review aims to consolidate the current understanding of bacterial sphingolipids and their impact on host health. Compared to mammalian sphingolipids, bacterial sphingolipids are characterized by odd chain lengths due to the presence of branched alkyl chains. Additionally, intestinal microbial sphingolipids can migrate from the gut to various host organs, affecting the immune system and metabolism. Furthermore, the intricate interplay between dietary sphingolipids and the gut microbiota is explored, shedding light on their complex relationship. Despite limited knowledge in this area, this review aims to raise awareness about the importance of bacterial sphingolipids and further our understanding of more uncharacterized bacterial sphingolipids and their significant role in maintaining host health.

KEYWORDS

sphingolipids, bacteria, gut microbiome, human health, interaction

1. Introduction

Sphingolipids are a group of lipids characterized by long-chain bases serving as the backbone, along with an amine group and two or three hydroxy groups at the structural end (Merrill, 2011). Sphingolipids, in the beginning, were thought to only exist in higher animals. However, subsequent research discovered sphingolipids in flagellates, rumen bacteria, protozoa, and specific Bacteroidaceae species such as *Bacteroides (B.) melaninogenicus* and *B. thetaiotaomicron*. These species are characterized by branched-chain sphingolipids (Stoffel et al., 1975; Olsen and Jantzen, 2001; Johnson et al., 2020; Le et al., 2022). As the gut microbiome and human health garner more attention, bacterial sphingolipids, particularly intestinal microbial sphingolipids, have gained interest due to their potential connections to gut microbiome and host health. Studies have shown that bacterial sphingolipids can be absorbed and detected in various organs throughout the body (Fukami et al., 2010; Johnson et al., 2020; Le et al., 2022). Additionally, sphingolipids produced by prominent *Bacteroidetes* in the gut have been found to impact host lipid metabolism and liver function (Johnson et al., 2020). Moreover, intestinal microbial sphingolipids play a significant role in maintaining host immune homeostasis (An et al., 2014; Brown et al., 2019). Despite the work of laboratories like Elizabeth Johnson's Lab at Cornell University, there have been relatively fewer reports on bacterial sphingolipids compared to mammal sphingolipids.

There is evidence suggesting that many microorganisms, microbial toxins, and viruses bind to cells through sphingolipids (Vesper et al., 1999) and bacteria can translocate to host

organs (Brown et al., 2019; Johnson et al., 2020). Several intriguing clinical phenomena have emerged, indicating the potential prospects of studying intestinal microbial sphingolipids in clinical research. For instance, it has been reported that dietary gangliosides may play a crucial role in modifying the intestinal microflora and promoting the development of intestinal immunity in neonates, thereby preventing infections during early infancy (Rueda, 2007). Another study examined the gut microbiome and neurodevelopment in infants from a general population birth cohort at two critical periods during infancy. The findings revealed that infants with a dominance of *Bacteroidetes* displayed enrichment in multiple metabolic functions, including sphingolipid metabolism and glycosphingolipid biosynthesis. This group of infants also achieved higher scores in cognitive, language, and motor development at the age of 2 years old (Tamana et al., 2021). These fragmented pieces of information emphasize the importance of investigating bacterial sphingolipids, including their unidentified compounds and structures, their impact on host physiology, and their role in connecting the gut microbiome with host health. Understanding how the daily diet influences the gut microbiome and its sphingolipids, as well as comprehending the mechanisms by which intestinal microbial activity affects host health, are important areas that require extensive research. It is clear that addressing these complex questions will require considerable effort and time.

This review provides a comprehensive overview of current knowledge regarding bacterial sphingolipids and their impact on host health. We will begin by introducing sphingolipids in general and highlight the structural differences between bacterial sphingolipids and those found in mammals. Additionally, we examine the influence of bacterial sphingolipids on the host's immune system and metabolites. Furthermore, we will explore the intricate relationship between dietary sphingolipids and the gut microbiota. Despite limited knowledge in this area, we aim to contribute to the understanding of bacterial sphingolipids. Our ultimate objective is to raise awareness and further investigate the importance of bacterial sphingolipids, particularly intestinal microbial sphingolipids, and provide potentials to develop targeted therapeutics for uncharacterized sphingolipids. Additionally, we aim to elucidate the underlying mechanisms by which these sphingolipids interact with the gut and influence host health.

2. An overview of sphingolipid structure and categories

2.1. Definition and categories of sphingolipids

Sphingolipids are a group of lipids characterized by a common structural feature: they all consist of "long-chain" bases, also known as "sphingoid" bases, as the backbone, along with an amine group and two or three hydroxy groups at the structural end. The representative sphingoid base is sphingosine, specifically (2S, 3R, 4E)-2-aminooctadec-4-ene-1,3-diol, which is also referred as (E)-sphing-4-enine (Wieland Brown et al., 2013; Taniguchi and Okazaki, 2021). The sphingoid bases can vary in terms of the number and arrangement of hydroxyl groups, the length of alkyl chains, and the presence of saturated or unsaturated bonds

(Merrill, 2011; **Figure 1**). Free sphingoid bases are present in minimal amounts, making them complex compounds. In case of complex sphingolipids, the amino group of the sphingoid bases undergoes acylation with fatty acids and/or a substituent at position 1 hydroxyl. The fatty acid chains can vary in length and number of double bonds, typically ranging from 14 to 36 carbon atoms and can be saturated, have a single double bond, or possess an α-hydroxyl group (Pruett et al., 2008). Common substituents include -H, fatty acids, phosphates, phosphocholine, phosphoethanolamine, galactose, glucose, sialic acid, sulfate, glucuronic acid, or a combination of these groups. Consequently, the potential diversity of lipid species is vast (Merrill et al., 2007). However, the actual number of species produced in biological systems is significantly lower, primarily due to the limited number of synthases involved in complex sphingolipid synthesis and their substrate specificities. In order to illustrate the sphingolipid structures clearly, the common structures were summarized in **Figure 1**.

Common sphingolipids include ceramide, sphingomyelin, glucosylceramide (GlcCer), lactosylceramide (LacCer), and galactosylceramides (GalCer). Additionally, there are more complex glycosphingolipids that contain a varying number of sugar residues. In addition to these, small amounts of sphingolipid analogs are present, along with "lyso-" sphingolipids. "Lyso-" sphingolipids refer to sphingoid bases combined with a headgroup but lacking the N-acyl substituent. Examples of "lyso-" sphingolipids include sphingosine 1-phosphate, sphingosine 1-phosphocholine, and lyso-glycosphingolipids (**Figure 1**). Moreover, there are *N*-methyl derivatives of sphingolipids and covalent adducts with proteins (Vesper et al., 1999; Merrill, 2011).

2.2. Bacterial sphingolipids

Initially, sphingolipids were believed to be present only in higher animals. However, further investigations have unveiled the presence of branched-chain sphingolipids in bacteria, including *Bacteroides*, *Prevotella*, *Sphingomonas*, *Sphingobacterium*, *Porphyromonas*, *Fusobacterium*, *Bdellovibrio*, *Cystobacter*, *Mycoplasma*, and *Flectobacillus*, which is noteworthy that a majority of these bacteria are anaerobes (Stoffel et al., 1975; Olsen and Jantzen, 2001).

In Stoffel et al. (1975) conducted an initial investigation on the lipid composition of anaerobic *B. thetaiotaomicron* metabolites. The analysis revealed that approximately 50% of the total lipid extract was sphingolipids, including sphingomyelin, ceramide phosphinicoethanolamine, free even-numbered and branched chain sphingosine bases and ceramide (Stoffel et al., 1975). More recently, in a germ-free mice mono-colonized with wild type *B. thetaiotaomicron* (BTWT) or *SPT* knocked *B. thetaiotaomicron* (BT$_\Delta$SPT), 144 unique bacterial lipids were identified using Tandem Mass Spectrometry, dependent on Spt, with 35 unique *Bacteroides* sphingolipids present in BTWT but absent in the BT$_\Delta$SPT. Among the differential sphingolipids, the most abundant ones in the BTWT-colonized mouse cecum were ceramide phosphoethanolamine (Cer-PE) and dihydroceramide (DHCer). Additionally, an abundant ceramide phosphoinositol (Cer-PI) was observed, a sphingolipid newly reported to be produced by gut *Bacteroides* strains and not detected in mammalian cells.

FIGURE 1
Overview of sphingolipids structure (Merrill, 2011). **(A)** Categorization of sphingolipid structures based on the "long chain" base; **(B)** categorization of sphingolipid structures based on the head group.

Furthermore, a subset of phosphatidylethanolamine (PE) that were significantly more abundant in BT$_\Delta$SPT-colonized mouse cecum was discovered, with PE 32:0 and PE 35:07 being the most differential *in vivo* (Brown et al., 2019). Another study found that *B. thetaiotaomicron* can synthesize a set of uncharacterized homoserine-containing sphingolipids that are transferred to the host liver (Le et al., 2022).

Lipidomics analysis of the outer membrane vesicles (OMVs) from *B. thetaiotaomicron* VPI-5482 revealed the presence of diverse sphingolipids, glycerophospholipids, and glycine-serine dipeptide lipids (GS). The most abundant sphingolipids identified were ethanolamine phosphoceramide (EPC) and

inositol phosphoceramide (IPC) (Sartorio et al., 2022). Another recent lipidomic analysis of four Bacteroides species reported that Dihydroceramide Phosphoethanolamine (DHCer-PE) is the most abundant sphingolipid across all four Bacteroides strains. Sphingolipids accounted for 19–29% of the total lipids detected in Bacteroides species, with DHCer making up approximately 20% of the sphingolipid fraction in *B. ovatus*, *B. vulgatus*, and *B. thetaiotaomicron*, but only 2% in *B. fragilis*. Instead, *B. fragilis* appeared to accumulate higher levels of keto-sphinganine (keto-sph). Additionally, detectable levels of sphinganine (sph) and deoxy-sph were found in both *B. thetaiotaomicron* and *B. ovatus*. α-Galactosylceramide (α-GalCer) was detected solely

in *B. fragilis* and *B. vulgatus* (Ryan et al., 2023). Hence, there exists a diverse array of sphingolipid compounds, suggesting the potential existence of multiple pathways involved in sphingolipid biosynthesis across various *Bacteroides* species.

In addition to the previous mentioned *Bacteroides*, a few members of the Chlorobi phylum, especially within genus *Chlorobium*, which are also capable of sphingolipid producing sphingolipids (Gupta and Lorenzini, 2007). Moreover, certain Alpha-Proteobacteria (such as *Acetobacter, Sphingomonas,* and *Novosphingobium*) and Delta-Proteobacteria (including *Myxococcus* and *Bdellovibrio*) are known to produce sphingolipids as well. While there are thousands of bacteria, only a small percentage of them are capable of producing sphingolipids (Table 1). Bacterial sphingolipids can be found in various environments, indicating the successful adaptation of sphingolipid producers in the biosphere (Fredrickson et al., 1995; Schubotz et al., 2009; Sollich et al., 2017; Heaver et al., 2018). For example, the human gastrointestinal tract is often heavily colonized by Bacteroidetes, including species like *Bacteroides* and *Prevotella* species, resulting to the existence of approximately 1 gram of sphingolipids produced by intestinal bacteria at any given time (Schnorr et al., 2014; Smits et al., 2017). Within the human gut, members of the Bacteroidetes phylum (e.g., *Bacteroides, Prevotella, Porphyromonas*) are known to synthesize sphingophospholipids that resemble sphingomyelin, a sphingolipid abundant in mammalian membranes. They also produce glycosphingolipids and DHCers (Stoffel et al., 1975; Olsen and Jantzen, 2001; Wieland Brown et al., 2013; Moye et al., 2016). Additionally, within the Bacteroidetes phylum, species such as *Chryseobacterium gleum, Alistipes,* and *Odoribacter* spp. were reported to synthesize sulfonolipids, as well (Walker et al., 2017; Heaver et al., 2018; Hou et al., 2022). Although the adaptation driving factors are unclear, it was reported that some pathogens, like *Bacillus cereus* (Flores-Díaz et al., 2016), *Clostridium perfringens* (Urbina et al., 2011), *Helicobacter pylori* (Chan et al., 2000), *Mycobacterium tuberculosis* (Speer et al., 2015), can survive in extreme environment because they produce sphingomyelinase, which degrade sphingomyelin (a kind of sphingolipids in cell membranes) and help pathogens invade into the host or escape from macrophage (Simonis and Schubert-Unkmeir, 2018). Moreover, certain opportunistic human pathogens, such as Sphingomonas species, are known to produce sphingolipids that likely originate from the plant rhizosphere (Berg et al., 2005). In the past years, increased human infections caused by opportunistic pathogens originating from the rhizosphere, which refers to the zone surrounding plant roots, have been noticed. It is worth noting that certain strains of Proteobacteria that are associated with plant roots can engage in interactions with both plants and humans. These particular strains have been found to possess beneficial effects on plant growth, displaying plant growth-promoting properties. Moreover, they have also shown excellent antagonistic properties against plant pathogens, offering potential benefits for both agricultural practices and the development of novel disease-control strategies (Berg et al., 2005; Bodenhausen et al., 2013; Erkosar and Leulier, 2014). This highlights the emerging significance of sphingolipid-producing *Proteobacteria* as important colonizers of both plants and animals. Examples include *Sphingomonas* spp. found on plant and root surfaces (Bodenhausen et al., 2013), as well as *Acetobacter* spp. associated with *Drosophila melanogaster*

and *Caenorhabditis elegans* (Ogawa et al., 2010; Erkosar and Leulier, 2014; Zhang et al., 2017). The bacteria mentioned above are just a subset of the numerous species known to produce sphingolipids and more information are illustrated in Table 1 and Figure 2.

2.3. The distinction between bacterial sphingolipids and eukaryotic sphingolipids

Recent research has uncovered that ability of both bacteria and eukaryotic organisms to produce sphingolipids (Olsen and Jantzen, 2001; Brown et al., 2019, 2023). However, there are notable distinctions between bacterial and eukaryotic sphingolipids. In mammals, the primary type of synthesized sphingolipids consists of even-chained linear structure. Conversely, bacterial sphingolipids exhibit a unique characteristic in which their sphingoid base has an odd chain length due to the presence of branched alkyl chains (Le et al., 2022; Ryan et al., 2023), like Threonine C_{19}, Homoserine C_{19}, and Serine/Alanine C_{35} DHCer, as well as Serine C_{37}/C_{35} DHCer-PE in wild *B. thetaiotaomicron* (Le et al., 2022).

The initial step of sphingolipid synthesis in both bacteria and eukaryotes involves the condensation of an amino acid (typically serine in mammals) and a fatty acid (typically palmitate in mammals) through the action of the serine palmitoyltransferase (SPT) enzyme. This enzyme is highly conserved in both eukaryotes and bacteria (Yard et al., 2007). However, after the initial step, the pathways and products of sphingolipid biosynthesis diverge between eukaryotes and bacteria, including 3-Ketodihydrosphingosine reductase (KDSR), Sphingosine kinases (SKs), Sphingosine 1-phosphate lyase (S1PL) (Harrison et al., 2018; Heaver et al., 2018). Nevertheless, our understanding of bacterial sphingolipids is still less comprehensive compared to their eukaryotic counterparts, and therefore, the exact differences remain unclear. The specific variations in bacterial sphingolipid synthesis compared to eukaryotic sphingolipid synthesis have yet to be fully elucidated due to the relatively limited knowledge about bacterial sphingolipids. Further research is required to gain a more comprehensive understanding of bacterial sphingolipids and their distinctions from eukaryotic sphingolipids.

3. Interaction of bacterial sphingolipids with the host

Efforts were undertaken to investigate the potential of bacterial sphingolipids to undergo transformation within the host organs. Fukami et al. (2010) conducted a study where ^{13}C-labeled ceramide extracted from *Acetobacter malorum* were orally administered to mice. And these sphingolipids were readily absorbed and metabolized in the liver, ultimately forming complex sphingolipids (Fukami et al., 2010). Recent experiments utilizing fluorescently labeled bacteria demonstrated the presence of sphingolipids originating from bacteria in various tissues such as the liver, colon, ileum, brain, and skin, through the intestinal epithelial cells (Brown et al., 2019; Hussain et al., 2019; Johnson et al., 2020;

TABLE 1 Known bacterium producing sphingolipids.

Bacterium	Sphingolipids	References
Acetobacter malorum	Ceramide	Ogawa et al., 2010
Alistipes finegoldii	Sulfonolipids	Radka et al., 2022
Algoriphagus machipongonensis	Sulfonolipids	Alegado et al., 2012
Alistipes and Odoribacter	Sulfonolipids	Walker et al., 2017
Bacteroides thetaiotaomicron	Cer-PE, Cer-PG, Cer PI, Cer-PC, DHCer, DHcer-PE, DHcer-PI, sphingoid base,	Olsen and Jantzen, 2001; Le et al., 2022; Ryan et al., 2023
Bacteroides fragilis	Cer-PE, Cer-PG, DHCer, α-GalCer	Olsen and Jantzen, 2001; Ryan et al., 2023
Bacteroides ovatus	Cer-PE, Cer-PG, Cer-PI DHCer Sphingoid base,	Olsen and Jantzen, 2001; Ryan et al., 2023
Bacteroides uniformis	Cer-PE, Cer-PG	Olsen and Jantzen, 2001
Bacteroides caccae	Cer-PE, Cer-PG	Olsen and Jantzen, 2001
Bacteroides eggerthii	Cer-PE, Cer-PG	Olsen and Jantzen, 2001
Bacteroides stercoris	Cer-PE, Cer-PG	Olsen and Jantzen, 2001
Bacteroides. vulgatus	DHCer, Cer PE, Cer PI, α-GalCer	Ryan et al., 2023
Bdellovibrio bacteriovorus	Sphingophospholipids	Olsen and Jantzen, 2001
Capnocytophaga ochracea	Sulfonolipid Capnine	Liu et al., 2022
Caulobacter crescentus	Cer-PG	Dhakephalkar et al., 2023
Chlamydia psittaci	Sphingomyelin	Koch-Edelmann et al., 2017
Chlamydia trachomatis	Sphingomyelin	Koch-Edelmann et al., 2017
Chryseobacterium gleum	Sulfonolipids	Chaudhari et al., 2009; Hou et al., 2022
Cystobacter fuscus	Sphingolipids	Olsen and Jantzen, 2001
Flectobacillus major	Amino sphingophospholipids (namely Cer-PC)	Olsen and Jantzen, 2001
Mycoplasma spp.	Sphingophospholipid	Olsen and Jantzen, 2001
Sphingobacterium spp.	Sphingolipids	Olsen and Jantzen, 2001
Porphyromonas gingivalis	DHCer	Moye et al., 2016
Prevotella melaninogenica	Cer-PE, Cer-PG	Olsen and Jantzen, 2001
Prevotella intermedia	Cer-PE, Cer-PG	Olsen and Jantzen, 2001
Prevotella bivia	Cer-PE, Cer-PG	Olsen and Jantzen, 2001
Porphyromonas gingivalis	Cer-PE, Cer-PG	Olsen and Jantzen, 2001
Sphingomonas spp	Sphingolipids	Olsen and Jantzen, 2001
Sphingomonas paucimobilis	GlcCer, α-GalCe	Yard et al., 2007
Sphingobacterium spiritivorum	Ceramide	Minamino et al., 2003
Salinibacter ruber	Sulfonolipid	Corcelli et al., 2004

Cer-PE, ceramide phosphoethanolamine; Cer-PG, ceramide phosphoglycerol; Cer-PC, ceramide phosphocholine; Cer PI, ceramide phosphoinositol; DHCer, dihydroceramide; α-GalCer, α-Galactosylceramide; DHCer-PE, dihydroceramide phosphoethanolamine; DHCer-PI, dihydroceramide phosphoinositol, GlcCer, glucosylceramide.

Le et al., 2022). These findings suggest that bacterial sphingolipids play an active role in maintaining are actively utilized in maintaining sphingolipid homeostasis and promoting symbiosis within the host. Furthermore, these results provide evidence for a direct connection between host and microbial sphingolipids, as depicted in Figure 3.

3.1. Implications of bacterial sphingolipids on the immune system

The interaction between bacterial sphingolipids and the host began with the identification of a lipid produced by members of the Bacteroidetes that is analogous to alpha-GC, a known CD1-binding lipid derived from *Sphingomonas* species (Brown et al., 2023). Early studies revealed that alpha-GC derived from *Bacteroides fragilis* has the ability to bind to both mouse CD1d and the T-cell receptor (TCR) on invariant natural killer T (iNKT) cells, thereby inhibiting iNKT cell proliferation during neonatal development (Wieland Brown et al., 2013; An et al., 2014). Subsequent investigations have further elucidated the structural requirements for efficient binding between alpha-GC and CD1d, as well as the functional consequences of alpha-GC recognition by the TCR. These studies have highlighted the role of alpha-GC in regulating colonic NKT cells, suggesting its structure-specific immunomodulatory activity (Oh et al., 2021). Moreover, administration of these sphingolipids

FIGURE 2
Sphingolipids represented structure mentioned in the Table 1. The formulas in the figure represent the representative structure, not the exact formulas.

to mice has been found to induce an anti-inflammatory effect and reduce the number of colonic NKT cells (Oh et al., 2021).

Further support for the impact of microbiome sphingolipids on host inflammatory and metabolic pathways was obtained

through experiments conducted on germ-free mice colonized with sphingolipid-deficient bacteria. These mice exhibited gut inflammation and alterations in host ceramide levels (Brown et al., 2019). The interaction of *Bacteroides* sphingolipids with

FIGURE 3
The potential link between host and microbial sphingolipids.

the innate immune system was also observed, as sphingolipids present in the outer membrane of *Bacteroides* facilitated a tolerant immune response. Studies on Bacteroidetes demonstrated that sphingolipids in outer membrane vesicles (OMVs) acted as agonists for TLR2 signaling in macrophages, thus playing a critical role in limiting inflammatory signaling (Rocha et al., 2021). Analysis of an inflammatory bowel disease (IBD) metabolomic dataset indicated reduced abundance of *Bacteroides* sphingolipids in IBD cases, along with negative correlations with inflammation and host sphingolipid production (Brown et al., 2019). These findings, coupled with the observation that bacterial sphingolipids are capable of translocating into the host (Yatsunenko et al., 2012), highlight the significance of bacterial sphingolipids in maintaining immune homeostasis.

3.2. Influence of bacterial sphingolipids on host metabolites

A recent study demonstrated that exposure of mice to *B. thetaiotaomicron*, a producer of sphingolipids, resulted in a reduction in the *de novo* production of sphingolipids by the host, while liver ceramide levels increased. Furthermore, experiments conducted on human cell cultures and mouse models confirmed that *Bacteroides* sphinganine can be taken up by host epithelial cells and incorporated into sphingolipid metabolic pathways. These findings suggest that gut-derived sphingolipids have an impact on host lipid metabolism and liver function (Johnson et al., 2020). Further investigation into the relationship between the gut and liver regarding sphingolipid signaling unveiled that the mere presence of microbiome sphingolipids was sufficient to reverse fatty liver disease in mice (Le et al., 2022). This indicates that microbiome sphingolipids not only exert local effects within the gut but also possess systemic effects by trafficking to organs beyond the intestine, thereby modulating host sphingolipid signaling.

4. Microorganisms and dietary sphingolipids

Sphingolipids are essentially widespread components found in various foods, especially in eggs and milk, that we consume on a daily basis (Andrieu-Abadie and Levade, 2002; Hussain et al., 2019), While it is believed that most sphingolipids, including sphingomyelin (SM), are not absorbed intact in the upper intestine, they do enter the distal small intestine, where they undergo degradation and give rise to bioactive lipids such as ceramide and sphingosine (Duan et al., 2007; Fischbeck et al., 2009; Norris et al., 2019). Research studies have indicated the presence of approximately 10% undegraded sphingomyelin and 30–90% ceramide in mouse feces (Norris et al., 2019). Furthermore, analysis of fecal metabolome of urban-dwelling Italians and the Hadza people of Tanzania revealed an overall abundance of sphingolipids (Turroni et al., 2016).

A study discovered that the addition of gangliosides, a type of sphingolipid, to infant formula had a significant impact on the intestinal ecosystem of preterm newborns. This supplementation led to an increase in the presence of *Bifidobacteria* and a decrease in the abundance of *Escherichia coli* (Rueda, 2007). *Bacteroidetes*, including *Bifidobacterium* strains, possess enzymes that can break down gangliosides, such as sialidases that release free sialic acid. This biochemical process contributes to the immunological functions and prevention of infections (Rueda, 2007; Lewis and Lewis, 2012). Interestingly, *Bifidobacterium* strains, despite lacking the ability to synthesize sphingolipids, can still import and utilize sphingolipids to generate DHCer (Lee et al., 2021). On the other hand, the pathogenic bacterium *Clostridium perfringens*, which can be found in stool samples, produces an enzyme called sphingomyelinase. This enzyme hydrolyzes sphingomyelin into ceramide and phosphocholine (Urbina et al., 2011; Wang et al., 2021).

In more recent findings, conclusive evidence of the microbial uptake of dietary sphinganine in the mouse gut has been established using a click-chemistry based method to trace the incorporation of bio-orthogonal dietary omega-alkynyl sphinganine into the gut microbial community. The study identified several bacterial genera, including *Bacteroides*, *Prevotella*, *Bifidobacterium*, *Lactobacillus*, and *Turicibacter*, as participants in the assimilation process of sphinganine. Of particular interest, over 99% of the bacteria involved in the assimilation were identified as *Bacteroides*, with *Prevotella* being the second most prevalent, albeit in much lesser abundance compared to *Bacteroides* (Lee et al., 2021). Based on these findings, it can be inferred that known sphingolipid-producing bacteria, primarily *Bacteroides*, play a dominant role in the metabolism of dietary sphinganine.

5. Conclusion

Among sphingolipids characterized by long-chain bases with an amine group and hydroxy groups at the structural end, bacterial sphingolipids consist of odd chain lengths due to the presence of branched alkyl chains, unlike mammalian sphingolipids. The interaction between bacterial sphingolipids and the host is a complex and dynamic process, although our understanding of

it is limited. Current knowledge suggests that bacterial sphingolipids have the ability to translocate from epithelial cells to body organs, thereby impacting the immune system and metabolism of the host. Furthermore, undegraded dietary sphingolipids in the distal small intestine are exposed to the gut microbiome, which can break them down into bioactive lipids. These findings emphasize the intricate interplay of sphingolipids within the host, underscoring the importance of bacterial sphingolipids in maintaining inner homeostasis and overall health.

However, our understanding of microbial sphingolipids in the gut is still limited, and further research is needed to fully explore their potential. Several key areas warrant investigation. Firstly, it is important to identify the specific bacteria responsible for sphingolipid production and characterize the types of sphingolipids they produce. Understanding the translocation mechanisms of these sphingolipids and their transformation processes is also essential. Additionally, investigating the functions of bacterial sphingolipids within the host, including their impact on the immune system and metabolic homeostasis, is crucial. Since the gut microbiome functions as a vital organ in the host, conducting more comprehensive studies in this field will provide valuable insights that can potentially lead to the development of therapeutics targeting sphingolipid metabolism and improving the various diseases. Advancements in these areas could have profound implications for human health and overall wellbeing.

Author contributions

XB: Writing – original draft. RY: Writing – review and editing. XT: Writing – review and editing. MC: Writing – review and editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

References

Alegado, R., Brown, L., Cao, S., Dermenjian, R., Zuzow, R., Fairclough, S., et al. (2012). A bacterial sulfonolipid triggers multicellular development in the closest living relatives of animals. *eLife* 1:e00013. doi: 10.7554/eLife.00013

An, D., Oh, S., Olszak, T., Neves, J., Avci, F., Erturk-Hasdemir, D., et al. (2014). Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. *Cell* 156, 123–133. doi: 10.1016/j.cell.2013.11.042

Andrieu-Abadie, N., and Levade, T. (2002). Sphingomyelin hydrolysis during apoptosis. *Biophys. Acta (BBA)Mol. Cell Biol. Lipids* 1585, 126–134.

Berg, G., Eberl, L., and Hartmann, A. (2005). The rhizosphere as a reservoir for opportunistic human pathogenic bacteria. *Environ. Microbiol.* 7, 1673–1685.

Bodenhausen, N., Horton, M., and Bergelson, J. (2013). Bacterial communities associated with the leaves and the roots of *Arabidopsis thaliana*. *PLoS One* 8:e56329. doi: 10.1371/journal.pone.0056329

Brown, E., Clardy, J., and Xavier, R. (2023). Gut microbiome lipid metabolism and its impact on host physiology. *Cell Host Microbe* 31, 173–186.

Brown, E., Ke, X., Hitchcock, D., Jeanfavre, S., Avila-Pacheco, J., Nakata, T., et al. (2019). *Bacteroides*-derived sphingolipids are critical for maintaining intestinal homeostasis and symbiosis. *Cell Host Microbe* 25, 668.e7–680.e7. doi: 10.1016/j.chom.2019.04.002

Chan, E., Chang, C., Li, Y., Chang, C., Chiou, C., and Wu, T. (2000). Purification and characterization of neutral sphingomyelinase from *Helicobacter* pylori. *Biochemistry* 39, 4838–4845. doi: 10.1021/bi9925423

Chaudhari, P., Wani, K., Chaudhari, B., and Chincholkar, S. (2009). Characteristics of sulfobacin A from a soil isolate *Chryseobacterium gleum*. *Appl. Biochem. Biotechnol.* 158, 231–241. doi: 10.1007/s12010-008-8417-7

Corcelli, A., Lattanzio, V., Mascolo, G., Babudri, F., Oren, A., Kates, M., et al. (2004). Novel sulfonolipid in the extremely halophilic bacterium *Salinibacter ruber*. *Appl. Environ. Microbiol.* 70, 6678–6685. doi: 10.1128/AEM.70.11.6678-6685.2004

Dhakephalkar, T., Stukey, G., Guan, Z., Carman, G., and Klein, E. (2023). Characterization of an evolutionarily distinct bacterial ceramide kinase from *Caulobacter crescentus*. *J. Biol. Chem.* 299:2023.05.01.538943. doi: 10.1016/j.jbc.2023.104894

Duan, R., Cheng, Y., Jönsson, B., Ohlsson, L., Herbst, A., Hellström-Westas, L., et al. (2007). Human meconium contains significant amounts of alkaline sphingomyelinase, neutral ceramidase, and sphingolipid metabolites. *Pediatr. Res.* 61, 61–66. doi: 10.1203/01.pdr.0000250534.92934.c2

Erkosar, B., and Leulier, F. (2014). Transient adult microbiota, gut homeostasis and longevity: Novel insights from the *Drosophila* model. *FEBS Lett.* 588, 4250–4257. doi: 10.1016/j.febslet.2014.06.041

Fischbeck, A., Krüger, M., Blaas, N., and Humpf, H. (2009). Analysis of sphingomyelin in meat based on hydrophilic interaction liquid chromatography coupled to electrospray ionization- tandem mass spectrometry (HILIC-HPLC-ESI-MS/MS). *J. Agric. Food Chem.* 57, 9469–9474. doi: 10.1021/jf9025376

Flores-Díaz, M., Monturiol-Gross, L., Naylor, C., Alape-Girón, A., and Flieger, A. (2016). Bacterial sphingomyelinases and phospholipases as virulence factors. *Microbiol. Mol. Biol. Rev.* 80, 597–628.

Fredrickson, J., Balkwill, D., Drake, G., Romine, M., Ringelberg, D., White, D., et al. (1995). Aromatic-degrading Sphingomonas isolates from the deep subsurface. *Appl. Environ. Microbiol.* 61, 1917–1922.

Fukami, H., Tachimoto, H., Kishi, M., Kaga, T., Waki, H., Iwamoto, M., et al. (2010). Preparation of 13C-labeled ceramide by *acetic acid bacteria* and its incorporation in mice. *J. Lipid Res.* 51, 3389–3395. doi: 10.1194/jlr.D009191

Gupta, R., and Lorenzini, E. (2007). Phylogeny and molecular signatures (conserved proteins and indels) that are specific for the *Bacteroidetes* and *Chlorobi* species. *BMC Evolut. Biol.* 7:71. doi: 10.1186/1471-2148-7-71

Harrison, P., Dunn, T., and Campopiano, D. (2018). Sphingolipid biosynthesis in man and microbes. *Nat Product Rep.* 35, 921–954.

Heaver, S., Johnson, E., and Ley, R. (2018). Sphingolipids in host–microbial interactions. *Curr. Opin. Microbiol.* 43, 92–99.

Hou, L., Tian, H., Wang, L., Ferris, Z., Wang, J., Cai, M., et al. (2022). Identification and biosynthesis of pro-inflammatory sulfonolipids from an opportunistic pathogen *Chryseobacterium gleum*. *ACS Chem. Biol.* 17, 1197–1206. doi: 10.1021/acschembio.2c00141

Hussain, G., Wang, J., Rasul, A., Anwar, H., Imran, A., Qasim, M., et al. (2019). Role of cholesterol and sphingolipids in brain development and neurological diseases. *Lipids Health Dis.* 18, 1–12.

Johnson, E., Heaver, S., Waters, J., Kim, B., Bretin, A., Goodman, A., et al. (2020). Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels. *Nat. Commun.* 11:2471. doi: 10.1038/s41467-020-16274-w

Koch-Edelmann, S., Banhart, S., Saied, E., Rose, L., Aeberhard, L., Laue, M., et al. (2017). The cellular ceramide transport protein CERT promotes *Chlamydia psittaci* infection and controls bacterial sphingolipid uptake. *Cell. Microbiol.* 19:e12752. doi: 10.1111/cmi.12752

Le, H., Lee, M., Besler, K., and Johnson, E. (2022). Host hepatic metabolism is modulated by gut microbiota-derived sphingolipids. *Cell Host Microbe* 30, 798–808. doi: 10.1016/j.chom.2022.05.002

Lee, M., Le, H., and Johnson, E. (2021). Dietary sphinganine is selectively assimilated by members of the mammalian gut microbiome. *J. Lipid Res.* 62:100034. doi: 10.1194/jlr.RA120000950

Lewis, A., and Lewis, W. (2012). Host sialoglycans and bacterial sialidases: A mucosal perspective. *Cell. Microbiol.* 14, 1174–1182. doi: 10.1111/j.1462-5822.2012.01807.x

Liu, Y., Wei, Y., Teh, T., Liu, D., Zhou, Y., Zhao, S., et al. (2022). Identification and characterization of the biosynthetic pathway of the sulfonolipid capnine. *Biochemistry* 61, 2861–2869. doi: 10.1021/acs.biochem.2c00102

Merrill, A. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. *Chem. Rev.* 111, 6387–6422. doi: 10.1021/cr2002917

Merrill, A., Wang, M., Park, M., and Sullards, M. (2007). (Glyco) sphingolipidology: An amazing challenge and opportunity for systems biology. *Trends Biochem. Sci.* 32, 457–468. doi: 10.1016/j.tibs.2007.09.004

Minamino, M., Sakaguchi, I., Naka, T., Ikeda, N., Kato, Y., Tomiyasu, I., et al. (2003). Bacterial ceramides and sphingophospholipids induce apoptosis of human leukaemic cells. *Microbiology* 149, 2071–2081. doi: 10.1099/mic.0.25922-0

Moye, Z., Valiuskyte, K., Dewhirst, F., Nichols, F., and Davey, M. (2016). Synthesis of sphingolipids impacts survival of *Porphyromonas gingivalis* and the presentation of surface polysaccharides. *Front. Microbiol.* 7:1919. doi: 10.3389/fmicb.2016.01919

Norris, G., Milard, M., Michalski, M., and Blesso, C. (2019). Protective properties of milk sphingomyelin against dysfunctional lipid metabolism, gut dysbiosis, and inflammation. *J. Nutr. Biochem.* 73:108224. doi: 10.1016/j.jnutbio.2019.108224

Ogawa, S., Tachimoto, H., and Kaga, T. (2010). Elevation of ceramide in *Acetobacter malorum* S24 by low pH stress and high temperature stress. *J. Biosci. Bioeng.* 109, 32–36. doi: 10.1016/j.jbiosc.2009.07.007

Oh, S., Praveena, T., Song, H., Yoo, J., Jung, D., Erturk-Hasdemir, D., et al. (2021). Host immunomodulatory lipids created by symbionts from dietary amino acids. *Nature* 600, 302–307.

Olsen, I., and Jantzen, E. (2001). Sphingolipids in bacteria and fungi. *Anaerobe* 7, 103–112.

Pruett, S., Bushnev, A., Hagedorn, K., Adiga, M., Haynes, C., Sullards, M., et al. (2008). Thematic review series: Sphingolipids. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. *J. Lipid Res.* 49, 1621–1639.

Radka, C., Miller, D., Frank, M., and Rock, C. (2022). Biochemical characterization of the first step in sulfonolipid biosynthesis in *Alistipes finegoldii*. *J. Biol. Chem.* 298:102195. doi: 10.1016/j.jbc.2022.102195

Rocha, F., Ottenberg, G., Eure, Z., Davey, M., and Gibson, I. F. (2021). Sphingolipid-containing outer membrane vesicles serve as a delivery vehicle to limit macrophage immune response to *Porphyromonas gingivalis*. *Infect. Immu.* 89:e00614-20. doi: 10.1128/IAI.00614-20

Rueda, R. (2007). The role of dietary gangliosides on immunity and the prevention of infection. *Br. J. Nutr.* 98, S68–S73. doi: 10.1017/S0007114507832946

Ryan, E., Gonzalez Pastor, B., Gethings, L., Clarke, D., and Joyce, S. (2023). Lipidomic analysis reveals differences in *Bacteroides* species driven largely by plasmalogens, glycerophosphoinositols and certain sphingolipids. *Metabolites* 13, 360. doi: 10.3390/metabo13030360

Sartorio, M., Valguarnera, E., Hsu, F., and Feldman, M. (2022). Lipidomics analysis of outer membrane vesicles and elucidation of the inositol phosphoceramide biosynthetic pathway in *Bacteroides* thetaiotaomicron. *Microbiol. Spectrum* 10:e0063421. doi: 10.1128/spectrum.00634-21

Schnorr, S., Candela, M., Rampelli, S., Centanni, M., Consolandi, C., Basaglia, G., et al. (2014). Gut microbiome of the Hadza hunter-gatherers. *Nat. Commun.* 5:3654.

Schubotz, F., Wakeham, S., Lipp, J., Fredricks, H., and Hinrichs, K. (2009). Detection of microbial biomass by intact polar membrane lipid analysis in the water column and surface sediments of the Black Sea. *Environ. Microbiol.* 11, 2720–2734. doi: 10.1111/j.1462-2920.2009.01999.x

Simonis, A., and Schubert-Unkmeir, A. (2018). The role of acid sphingomyelinase and modulation of sphingolipid metabolism in bacterial infection. *Biol. Chem.* 399, 1135–1146. doi: 10.1515/hsz-2018-0200

Smits, S., Leach, J., Sonnenburg, E. D., Gonzalez, C., Lichtman, J., Reid, G., et al. (2017). Seasonal cycling in the gut microbiome of the Hadza hunter-gatherers of Tanzania. *Science* 357, 802–806. doi: 10.1126/science.aan4834

Sollich, M., Yoshinaga, M., Häusler, S., Price, R., Hinrichs, K., and Bühring, S. (2017). Heat stress dictates microbial lipid composition along a thermal gradient in marine sediments. *Front. Microbiol.* 8:1550. doi: 10.3389/fmicb.2017.01550

Speer, A., Sun, J., Danilchanka, O., Meikle, V., Rowland, J., Walter, K., et al. (2015). Surface hydrolysis of sphingomyelin by the outer membrane protein R v0888 supports replication of M ycobacterium tuberculosis in macrophages. *Mol. Microbiol.* 97, 881–897. doi: 10.1111/mmi.13073

Stoffel, W., Dittmar, K., and Wilmes, R. (1975). Sphingolipid metabolism in *Bacteroideaceae*. *J. Biol. Chem.* 356, 715–725.

Tamana, S., Tun, H., Konya, T., Chari, R., Field, C., Guttman, D., et al. (2021). *Bacteroides*-dominant gut microbiome of late infancy is associated with enhanced neurodevelopment. *Gut Microbes* 13:1930875. doi: 10.1080/19490976.2021.1930875

Taniguchi, M., and Okazaki, T. (2021). Role of ceramide/sphingomyelin (SM) balance regulated through "SM cycle" in cancer. *Cell. Signal.* 87:110119. doi: 10.1016/j.cellsig.2021.110119

Turroni, S., Fiori, J., Rampelli, S., Schnorr, S., Consolandi, C., Barone, M., et al. (2016). Fecal metabolome of the Hadza hunter-gatherers: A host-microbiome integrative view. *Sci. Rep.* 6:32826. doi: 10.1038/srep32826

Urbina, P., Flores-Díaz, M., Alape-Girón, A., Alonso, A., and Goñi, F. (2011). Effects of bilayer composition and physical properties on the phospholipase C and sphingomyelinase activities of *Clostridium perfringens* α-toxin. *Bioch. Biophys. Acta Biomem.* 1808, 279–286.

Vesper, H., Schmelz, E., Nikolova-Karakashian, M., Dillehay, D., Lynch, D., and Merrill, A. Jr. (1999). Sphingolipids in food and the emerging importance of sphingolipids to nutrition. *J. Nutr.* 129, 1239–1250.

Walker, A., Pfitzner, B., Harir, M., Schaubeck, M., Calasan, J., Heinzmann, S., et al. (2017). Sulfonolipids as novel metabolite markers of *Alistipes* and *Odoribacter* affected by high-fat diets. *Sci. Rep.* 7:11047. doi: 10.1038/s41598-017-10369-z

Wang, B., Dong, W., Ma, L., Dong, Y., Wang, S., Yuan, Y., et al. (2021). Prevalence and genetic diversity of *Clostridium perfringens* isolates in hospitalized diarrheal patients from Central China. *Infect. Drug Resist.* 14, 4783–4793. doi: 10.2147/IDR.S338593

Wieland Brown, L., Penaranda, C., Kashyap, P., Williams, B., Clardy, J., Kronenberg, M., et al. (2013). Production of α-galactosylceramide by a prominent member of the human gut microbiota. *PLoS Biol.* 11:e1001610. doi: 10.1371/journal.pbio.1001610

Yard, B., Carter, L., Johnson, K., Overton, I., Dorward, M., Liu, H., et al. (2007). The structure of serine palmitoyltransferase; gateway to sphingolipid biosynthesis. *J. Mol. Biol.* 370, 870–886.

Yatsunenko, T., Rey, F., Manary, M., Trehan, I., Dominguez-Bello, M., Contreras, M., et al. (2012). Human gut microbiome viewed across age and geography. *Nature* 486, 222–227.

Zhang, F., Berg, M., Dierking, K., Félix, M., Shapira, M., Samuel, B., et al. (2017). Caenorhabditis elegans as a model for microbiome research. *Front. in Microbiol.* 8:485. doi: 10.3389/fmicb.2017.00485